Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Protein Expression Analysis to Confirm CAR Construct Stability and Function in Patient-Derived T-Cells

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Protein Expression Analysis to Confirm CAR Construct Stability and Function in Patient-Derived T-Cells

CAR Construct Stability and Function Analysis in Patient-Derived T-Cells

CELL & GENE | RNA | BIOLOGICS

Quantifying CAR Expression for Predictable Therapeutic Potency.

    What flow cytometry panels are used to confirm CAR expression and T-cell phenotype?

    A: We employ validated, multi-color flow cytometry panels designed to simultaneously quantify surface CAR expression using anti-Fab or anti-idiotype antibodies, while also characterizing T-cell subsets (e.g., CD4+, CD8+), memory phenotypes (Tscm, Tcm, Tem, Temra), and exhaustion markers (e.g., PD-1, TIM-3, LAG-3).

    How do you normalize protein expression data across different patient lots?

    A: Normalization is achieved using a combination of standardized instrument settings, compensation controls, and reference standards such as commercially available CAR-T cells or an internally developed cell line with stable CAR expression. This ensures run-to-run and lot-to-lot comparability for IND-enabling studies.

    What functional assays complement the protein expression analysis?

    A: To correlate CAR expression with cell function, we perform parallel assays including cytokine release profiling (Luminex/ELISA), cytotoxicity assays against target antigen-expressing tumor cells, and proliferation assays upon antigen stimulation. This provides a comprehensive potency assessment.

    What is the typical sample input and turnaround time?

    A: Sample requirements are defined based on specific project needs, and our flexible GxP workflows can accommodate a range of cell numbers. Turnaround times for a comprehensive data package are project-dependent and are established to meet program timelines.

Confirming stable, surface-level expression of the Chimeric Antigen Receptor (CAR) construct is a foundational step in de-risking a cell therapy candidate. Inconsistent or low expression directly impacts therapeutic potency and can lead to clinical failure. Our protein expression services utilize quantitative, multi-parametric flow cytometry to precisely measure CAR density on patient-derived T-cells, correlate expression with functional activity, and provide the robust characterization data required for regulatory submissions.

Verifying CAR Construct Expression for Clinical Translation

The therapeutic efficacy of a CAR-T cell product depends directly on the successful transduction, translation, and surface trafficking of the engineered CAR protein. Variability in manufacturing processes or patient starting material can lead to heterogeneous expression levels, impacting the product’s ability to recognize and eliminate target tumor cells.

A rigorous bioanalytical program provides a quantitative assessment of:

  • The percentage of CAR-positive T-cells in the final product.

  • The mean fluorescence intensity (MFI) as a surrogate for CAR density per cell.

  • The stability of CAR expression over time in culture.

  • The phenotype of the CAR-expressing T-cell subsets.

This quantitative approach helps establish key quality attributes (CQAs) and ensure lot-to-lot consistency for the product.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Multi-Parametric Flow Cytometry for Quantitative Assessment

We use high-parameter flow cytometry to build a detailed profile of the final cell therapy product. This approach allows for the simultaneous evaluation of the CAR construct and the underlying T-cell biology. By linking the physical expression of the CAR to specific T-cell memory and exhaustion phenotypes, we help build a more predictive data package for clinical performance.

Addressing Immunogenicity and Vector Efficiency

The introduction of a synthetic CAR protein can elicit an immune response. As research into T cell-mediated responses following gene transfer has shown, host immune systems can recognize and target cells expressing novel, non-self proteins (PMID: 17579582). Characterizing the potential for such a response is a key part of the safety profile.

The efficiency of the viral vector used for transduction is a primary determinant of the final product’s quality. Studies exploring alternative vectors to overcome pre-existing immunity highlight the importance of achieving efficient gene delivery to target immune cells (PMID: 12718764). Verifying high transduction efficiency through protein expression analysis confirms that the manufacturing process is robust and capable of producing a potent therapeutic population.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

Integrated Bioanalytical Support for IND Submission

The data generated from these protein expression and functional analyses form a core component of the Chemistry, Manufacturing, and Controls (CMC) section of an Investigational New Drug (IND) application. At our >100,000 sq ft GxP-compliant facility, we generate the high-quality, reproducible data needed to support an accelerated 18-24 month IND timeline. Since the Franklin Biolabs brand launch in 2024, our scientific leadership team has maintained its prior track record of a 100% IND success rate dating back to 2019.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities